Immuron Limited (AU:IMC) has released an update.
Immuron Limited, an Australian biopharmaceutical company, has announced a $2.3 million research grant awarded by the U.S. Department of Defense to further develop Travelan, their product aimed at preventing infectious diarrhea in military personnel. This funding will aid in enhancing Travelan’s formulation to combat diarrheal pathogens that are increasingly resistant to antibiotics and affect troops’ operational readiness. The research will be a collaborative effort with the Naval Medical Research Command and the Walter Reed Army Institute of Research to create a more effective prophylactic treatment for enteric diseases.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
